Check out her article at BioProcess Online.
1622 NW 55th Place
Gainesville, FL 32653
20 TW Alexander Dr, Suite 130
RTP, NC 27703
Tag Archive for: cdmo
New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies.
Gainesville, Florida (September 16, 2024) – Kincell Bio, a cell therapy-focused cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new client for the production of a cell therapy product to address degenerative disease.
The agreement represents a multi-year partnership to produce patient-specific batches of clinical-grade product at its site in Gainesville, Florida. The multi-year contract adds to the work for other clients already in progress at the site.
“We’re delighted to welcome another client to our Gainesville facility,” said Bruce Thompson, PhD., CEO of Kincell Bio. “Our facility is GMP-ready, and our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”
The client is a clinical stage cell therapy company pursuing regenerative medicine in a variety of critical indications. This project reflects Kincell Bio’s expanding portfolio, reinforcing its position as a strong partner in the cell therapy CDMO space.
About Kincell Bio
Kincell Bio engineers cells into therapies. A technology-forward contract development and manufacturing organization (CDMO), Kincell has facilities in both Gainesville, FL and Durham, NC. Kincell was formed to streamline analytical development, process development, CMC consulting and early-stage through registrational GMP cell therapy manufacturing. For more information, visit www.kincellbio.com.
Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com
New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies.
Durham, North Carolina (September 4, 2024) – Kincell Bio, a technology-forward cell therapy cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new partner for the production of early-phase clinical material of an allogeneic cell therapy product. This contract follows the acquisition of the GMP-ready facility in April 2024 and augments the manufacturing activities already occurring at the site. The agreement represents a multi-year relationship and strongly validates the team’s competency in allogeneic cell therapy production and release.
The partner is a leading biotechnology company known for pioneering advancements in novel biologic medicines. This collaboration underscores our shared commitment to driving innovation in the development and manufacturing of cutting-edge therapies aimed at addressing unmet medical needs.
“Kincell Bio continues to build meaningful partnerships with our customers, providing critical CMC development and manufacturing expertise to support their clinical trials”, said Bruce Thompson, PhD., CEO of Kincell Bio. “Our entire team is energized to support innovative approaches that help bring new cellular therapies to market and help patients.”
This new contract exemplifies Kincell Bio’s ongoing efforts to expand its portfolio of partnerships and enhance its manufacturing capabilities, reinforcing its position as a strong partner in the cell therapy CDMO space.
About Kincell Bio
Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC and Gainesville, FL, Kincell is a contract development and manufacturing organization (CDMO) situated in the Southeastern United States. Kincell Bio’s mission is to streamline CMC development, with expertise in analytical and process development and GMP manufacturing, testing and release. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs. For more information, visit www.kincellbio.com.
Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com
Check out her article at Cell & Gene.